TerminatedPhase 3NCT02055781
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
Studying Primary myelofibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CTI BioPharma
- Principal Investigator
- Simran SinghSr. Director, Head of Clinical Operations
- Intervention
- Pacritinib(drug)
- Enrollment
- 311 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2016
Study locations (30)
- Mayo Clinic Arizona, Scottsdale, Arizona, United States
- Arizona Clinical Research Center, Tucson, Arizona, United States
- City of Hope, Duarte, California, United States
- Moores Cancer Centre, La Jolla, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Stanford Cancer Center, Stanford, California, United States
- Rocky Mountain Cancer Center, Boulder, Colorado, United States
- George Washington University- Medical Faculty Associates, Washington D.C., District of Columbia, United States
- SCRI- Florida Cancer Specialists South Region, Fort Myers, Florida, United States
- SCRI - Florida Cancer Specialists North Region, St. Petersburg, Florida, United States
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- Carle Cancer Center, Urbana, Illinois, United States
- Indiana University Goshen Cancer Centre, Goshen, Indiana, United States
- Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02055781 on ClinicalTrials.govOther trials for Primary myelofibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07104799Momelotinib During and After HCT in MyelofibrosisMassachusetts General Hospital
- RECRUITINGPHASE3NCT07317700A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk MyelofibrosisChengdu Zenitar Biomedical Technology Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT07128381Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)M.D. Anderson Cancer Center
- RECRUITINGPHASE1, PHASE2NCT06887803A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsiOnctura
- RECRUITINGPHASE1, PHASE2NCT07281781Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowUniversity of California, Irvine
- ACTIVE NOT RECRUITINGNCT07342712Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation LevelsFirst Affiliated Hospital of Zhejiang University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06909136A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With MyelofibrosisSuzhou Junjing BioSciences Co., Ltd.
- RECRUITINGPHASE2NCT06770842Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisThe University of Hong Kong